News
HRTX
1.210
-2.42%
-0.030
Heron Therapeutics' Q1 revenue falls as oncology sales drop
Reuters · 21m ago
Heron Therapeutics misses top-line and bottom-line estimates; reaffirms FY26 outlook
Seeking Alpha · 30m ago
*Heron Therapeutics 1Q Sales $34.7M >HRTX
Dow Jones · 30m ago
*Heron Therapeutics Backs 2026 Rev $173M-$183M >HRTX
Dow Jones · 30m ago
BRIEF-Heron Therapeutics Q1 EPS USD -0.04
Reuters · 33m ago
HERON THERAPEUTICS INC: REAFFIRMED 2026 FULL-YEAR GUIDANCE OF $173-$183 MLN NET REVENUE
Reuters · 34m ago
Press Release: Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
Dow Jones · 34m ago
*Heron Therapeutics 1Q Loss/Shr 4c >HRTX
Dow Jones · 34m ago
Press Release: Heron Therapeutics Announces First -2-
Dow Jones · 34m ago
Earnings Scheduled For May 11, 2026
Benzinga · 1h ago
Weekly Report: what happened at HRTX last week (0504-0508)?
Weekly Report · 2h ago
Heron Therapeutics: Q1 Earnings Snapshot
Barchart · 5h ago
Here are the major earnings before the open Monday
Seeking Alpha · 14h ago
Heron Therapeutics Q1 2026 Earnings Preview
Seeking Alpha · 2d ago
Weekly Report: what happened at HRTX last week (0427-0501)?
Weekly Report · 05/04 09:40
Heron Therapeutics to report first-quarter results, host conference call and webcast
PUBT · 04/27 21:30
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
Barchart · 04/27 16:30
Weekly Report: what happened at HRTX last week (0420-0424)?
Weekly Report · 04/27 09:40
Weekly Report: what happened at HRTX last week (0413-0417)?
Weekly Report · 04/20 09:39
Heron Therapeutics (HRTX): Buy Rating on Expanding Hospital Product Adoption and Attractive Risk‑Reward
TipRanks · 04/16 19:15
More
Webull provides a variety of real-time HRTX stock news. You can receive the latest news about Heron Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutics that improve medical care. Its acute care product portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low-dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist indicated for postoperative nausea and vomiting in adults. CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and anthracycline and cyclophosphamide combination chemotherapy regimens.